LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer
April 04 2023 - 8:30AM
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE” or the
“Company”), a clinical-stage drug discovery company developing
pharmacologically active drugs for use in cancer treatment,
announced that Sarah Cannon Research Institute (SCRI) ) at
Tennessee Oncology in Nashville, Tennessee, is joining an ongoing
Phase 1b clinical trial initiated at City of Hope, one of the
largest cancer research and treatment organizations in the United
States, to assess the combination of LIXTE’s first-in-class protein
phosphatase 2A (PP2A) inhibitor LB-100 with a standard regimen for
previously untreated, extensive stage disease small cell lung
cancer (ED-SCLC) (NCT04560972).
City of Hope continues as the coordinating
center for the trial with Ravi Salgia, M.D., PhD, as the principal
investigator. The SCRI component of the trial will be led by
Melissa Johnson, M.D. Drs. Salgia and Johnson are nationally
recognized leaders in lung cancer research and care.
John S. Kovach, M.D., LIXTE’s founder and Chief
Executive Officer, commented, “We are excited to have SCRI at
Tennessee Oncology joining this important clinical trial. The
involvement of SCRI, one of the world’s leading oncology research
organizations, is expected to increase the accrual of patients to
this clinical trial, thus reducing the time required to demonstrate
the feasibility, tolerability, and efficacy of adding LB-100 to
this regimen. If a significant improvement in outcome is seen with
the addition of LB-100 to this regimen, this would be an important
advance in the treatment of this very aggressive disease.”
Ravi Salgia, M.D., Ph.D., City of Hope’s
Arthur & Rosalie Kaplan Chair in Medical Oncology, commented,
“City of Hope is pleased that this trial is continuing and will be
accessible to more small cell lung cancer patients who are in need
of more therapeutics options.”
Melissa Johnson, M.D., Director, Lung Cancer
Research, SCRI, commented, “Small cell lung cancer is a very
aggressive cancer with few therapeutic advances in recent years. We
remain committed to identifying and advancing novel therapies for
these patients. Dr. Salgia’s protocol adds Lixte’s lead compound,
LB-100, to both chemotherapy and immunotherapy in a promising new
approach to this disease.”
About LIXTE Biotechnology
Holdings, Inc.LIXTE Biotechnology
Holdings, Inc. is a clinical-stage pharmaceutical company
focused on new targets for cancer drug development and developing
and commercializing cancer therapies. LIXTE has achieved a
breakthrough with its novel, first-in-class lead clinical compound
and PP2A inhibitor, LB-100, demonstrating that LB-100 is
well-tolerated in cancer patients at doses associated with
anti-cancer activity. Based on extensive published preclinical data
(see www.lixte.com), LB-100 has the potential to significantly
improve outcomes for patients undergoing various chemotherapies or
immunotherapies. LIXTE's new approach has no known competitors and
is covered by a comprehensive patent portfolio. Initial
proof-of-concept clinical trials are in progress.
About City of Hope
City of Hope's mission is to deliver the cures
of tomorrow to the people who need them today. Founded in
1913, City of Hope has grown into one of the largest
cancer research and treatment organizations in the U.S. and one of
the leading research centers for diabetes and other
life-threatening illnesses. City of Hope research has been the
basis for numerous breakthrough cancer medicines, as well as
human synthetic insulin and monoclonal antibodies. With an
independent, National Cancer Institute-designated comprehensive
cancer center at its core, City of Hope brings a uniquely
integrated model to patients spanning cancer care, research and
development, academics and training, and innovation initiatives.
City of Hope’s growing national system includes its Los Angeles
campus, a network of clinical care locations across Southern
California, a new cancer center in Orange County, California, and
treatment facilities in Atlanta, Chicago and Phoenix. City of
Hope’s affiliated group of organizations
includes Translational Genomics Research
Institute and AccessHope. For more information about City
of Hope, follow us
on Facebook, Twitter, YouTube, Instagram and LinkedIn.
About Sarah Cannon Research
Institute
Sarah Cannon Research Institute (SCRI) is one of
the world’s leading oncology research organizations conducting
community-based clinical trials. In 2022, SCRI formed a joint
venture with US Oncology Research to enhance clinical trial access
and availability across the country. Focused on advancing therapies
for patients over the last three decades, SCRI is a leader in drug
development. It has conducted more than 600 first-in-human clinical
trials since its inception and contributed to pivotal research that
has led to the majority of new cancer therapies approved by the FDA
today. SCRI’s research network brings together physicians who are
actively accruing patients to clinical trials at more than 250
locations in 26 states across the United States.
---Forward-Looking
Statements
This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future activities, including the continuing development of
proprietary compounds, the planning, funding, coordination and
potential results of clinical trials, and the patent and legal
costs to protect and maintain the Company's intellectual property
worldwide, are all forward-looking statements. These statements are
generally accompanied by words such as "intend," anticipate,"
"believe," "estimate," "potential(ly)," "continue," "forecast,"
"predict," "plan," "may," "will," "could," "would," "should,"
"expect" or the negative of such terms or other comparable
terminology. The Company believes that the assumptions and
expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings
with the United States Securities and Exchange Commission
at https://www.sec.gov.
For more information about
LIXTE, Contact:info@lixte.comGeneral Phone: (631)
830-7092Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor
Relationspwinvestor@pondel.comRoger Pondel: (310) 279-5965Laurie
Berman: (310) 279-5962
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From Apr 2023 to Apr 2024